Table 3 Subgroup analyses of association with disease stage meta-analysis
Parameter | Subgroupa | ORb | Parameter | Subgroups | ORb |
|---|---|---|---|---|---|
Country of origin | Japan (n = 5) | 10.48 (4.82 to 22.78; I2 = 0) | Histologic tumor type | TCC (n = 9) | 7.91 (4.60 to 13.61; I2 = 0) |
| Â | Other (n = 7) | 5.20 (2.21 to 12.25; I2 = 22.7%) | Â | Not reported or TCC+other components (n = 3) | 3.94 (0.35 to 43.85; I2 = 51.1%) |
Cell separation method | Ficoll-Hypaque centrifugation ± further methods (n = 5) | 5.07 (2.48 to 10.35; I2 = 0) | Sampling time | Pretreatment or ≥7 days post-chemotherapy (n = 9 | 8.24 (4.63 to 14.68; I2 = 0) |
| Â | CellSearch method (n = 3) | 7.43 (1.52 to 36.25; I2 = 22.4%) | Â | NR or miscellany (n = 3) | 3.95 (0.36 to 43.95; I2 = 71.0%) |
| Â | Other protocols or NR (n = 4) | 13.57 (5.27 to 34.95; I2 = 0) | Â | Â | Â |
Blood sample volume | ≤7.5 ml (n = 6) | 9.36 (4.65 to 18.86; I2 = 0) | Collection of two consecutive blood samples | Yes (n = 4) | 4.25 (1.56 to 11.62; I2 = 21.1%) |
| Â | > 7.5 ml (n = 6) | 5.00 (2.27 to 11.00; I2 = 0) | Â | No (n = 8) | 9.53 (4.88 to 18.62; I2 = 0) |
Molecular detection technique | RT-PCR based (including nested RT-PCR; n = 7) | 8.36 (4.62 to 15.13; I2 = 0) | Nested RT-PCR method | Yes (n = 6) | 7.53 (4.09 to 13.85; I2 = 0) |
| Â | Other (n = 5) | 4.55 (1.07 to 19.35; I2 = 34.7%) | Â | No (n = 6) | 7.21 (1.66 to 31.28; I2 = 47.0%) |
PCR marker usedc | CK-20 (n = 5) | 5.47 (2.80 to 10.68; I2 = 0) | Â | Â | Â |
| Â | UP II (n = 3) | 1.59 (0.10 to 25.27; I2 = 89.8%) | Â | Â | Â |
| Â | Other (n = 3) | 17.50 (3.98 to 77.03; I2 = 0) | Â | Â | Â |